Home > Topoisomerase & > Gatifloxacin

Gatifloxacin

加替沙星,AM-1155,CG-5501,CG 5501,CG5501,BMS-206584,AM 1155,AM1155,BMS206584,BMS 206584

Gatifloxacin是第四代氟喹诺酮类抗生素，能抑制细菌的DNA旋转酶和拓扑异构酶IV。

目录号
EY1484
EY1484
EY1484
纯度
99.52%
99.52%
99.52%
规格
500 mg
1 g
5 g
原价
390
485
950
售价
390
485
950
库存
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, and inhibits the bacterial enzymes DNA gyrase and topoisomerase IV.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Alvirez-Freites EJ, et al. Antimicrob Agents Chemother, 2002, 46(4), 1022-1025.

    分子式
    C19H22FN3O4    		 分子量
    375.39    		 CAS号
    112811-59-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    10 mM    		 Water
    <1 mg/mL    		 Ethanol
    <1 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00350363 Ophthalmic Surgery Drug: Zymar Stanford University Phase 4 2007-01-01 2015-01-26
    NCT00905762 Healthy Drug: Gatifloxacin|Drug: Moxifloxacin|Drug: Besifloxacin Bausch & Lomb Incorporated Phase 1 2009-03-01 2011-12-07
    NCT01330355 Bacterial Conjunctivitis Drug: Besivance|Drug: Gatifloxacin Bausch & Lomb Incorporated Phase 3 2011-05-01 2014-09-02
    NCT00892918 Primary Pterygium Drug: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3% Meir Medical Center 2009-06-01 2009-05-04
    NCT01421693 Enteric Fever|Typhoid Fever Drug: Ceftriaxone|Drug: Gatifloxacin Oxford University Clinical Research Unit, Vietnam|University of Oxford|Patan Academy of Health Sciences, Nepal|Patan Hospital, Nepal|Civil Hospital, Nepal Phase 4 2011-09-01 2016-10-02
    NCT01218737 Infection and Inflammation After Refractive Surgery (Lasik). Drug: 0.3% gatifloxacin and 1.0% prednisolone acetate association|Drug: isolated 0.3% gatifloxacin and 1.0% prednisolone acetate Federal University of So Paulo|Allergan Phase 3 2009-01-01 2010-10-14
    NCT00335231 Endophthalmitis Drug: gatifloxacin ophthalmic (ZYMAR) Queen's University 2006-06-01 2007-05-17
    NCT00824070 Cataract Extraction Drug: Besifloxacin hydrochloride|Drug: moxifloxacin hydrochloride|Drug: gatifloxacin Bausch & Lomb Incorporated Phase 1 2009-02-01 2011-12-07
    NCT02980523 Bacterial Conjunctivitis Drug: PRO-157|Drug: Vigamox|Drug: Zymar|Drug: Lagricel Ofteno Laboratorios Sophia S.A de C.V. Phase 2 2015-03-01 2016-11-29
    NCT00396084 TB Multi-drug Resistant Drug: Gatifloxacin|Drug: Levofloxacin|Drug: Moxifloxacin|Drug: Isoniazid|Drug: Linezolid National Institute of Allergy and Infectious Diseases (NIAID) Phase 1|Phase 2 2004-02-01 2011-06-09
    NCT00569881 Corneal Epithelial Wound Healing Drug: gatifloxacin and moxifloxacin Donnenfeld, Eric, M.D. 2007-01-01 2007-12-07
    NCT00466570 Conjunctical Flora Drug: gatifloxacin, moxifloxacin Stanford University 2007-04-01 2013-06-12
    NCT00414011 Epithelium, Corneal Drug: Moxifloxacin|Drug: Gatifloxacin Walter Reed Army Medical Center 2013-06-26
    NCT00518089 Bacterial Conjunctivitis Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops Allergan Phase 3 2008-02-01 2011-10-24
    NCT00509873 Bacterial Conjunctivitis Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops Allergan Phase 3 2007-08-01 2011-10-24
    NCT00464438 Bacterial Conjunctivitis Drug: gatifloxacin|Drug: moxifloxacin 0.5% eye drops Allergan Phase 4 2007-06-01 2011-08-17
    NCT00651586 Acute Bacterial Corneal Ulcers|Bacterial Keratitis Drug: Gatifloxacin 0.3% ophthalmic solution|Drug: Ciprofloxacin 0.3% ophthalmic solution Allergan Phase 2 2003-10-01 2008-07-25
    NCT00216385 Tuberculosis Drug: Gatifloxacin combined regimen Institut de Recherche pour le Developpement|World Health Organization|European Commission Phase 3 2005-01-01 2005-09-20
    NCT00347828 Eye Infection|Infection Drug: Moxifloxacin ophthalmic solution 0.5%|Drug: Gatifloxacin ophthalmic solution 0.3% Ophthalmic Consultants of Boston|Allergan Phase 4 2006-06-01 2006-07-03
    NCT01928693 Corneal Ulcers Drug: Besivance 0.6% Ophthalmic Suspension|Drug: Zymaxid 0.5% Ophthalmic Solution|Drug: Vigamox 0.5% Ophthalmic Solution Cornea Consultants Of Nashville|SCRI Development Innovations, LLC|Bausch & Lomb Incorporated Phase 2 2013-07-01 2015-08-11
    NCT00874887 Anti-biotic Resistance Drug: moxifloxacin 0.5% HCI ophthalmic solution|Drug: gatifloxacin ophthalmic solution 0.3% Allergan Phase 4 2009-03-01 2011-11-16
    NCT00410891 Intravitreous|Injections Drug: gatifloxacin Stanford University Phase 4 2008-07-01 2014-05-13
    NCT00382460 Actue Coronary Syndromes Drug: PRAVASTATIN SODIUM Bristol-Myers Squibb Phase 4 2000-11-01 2011-04-07
    NCT00703313 Healthy Drug: 1.5% levofloxacin ophthalmic solution|Drug: 0.5% moxifloxacin hydrochloride ophthalmic solution|Drug: 0.3% gatifloxacin ophthalmic solution Santen Inc. Phase 4 2008-05-01 2009-02-04

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：